groups. In addition, the median time to engraftment was 19 days in the Prevymis treatment arm vs. 18 in the placebo arm.
Prevymis, a non-nucleoside CMV inhibitor (3,4 dihydro-quinazoline), inhibits viral replication through targeting the viral terminase complex. Prevymis will be available as 240mg and 480mg strength tablets in 4 Dosepaks, each containing a 7-count blister card (28 tablets total) or as a carton containing 2 blister cards, each containing a 7-count blister card (14 tablets total). Prevymis injection will be available in 240mg (12mL vial) and 480mg (24mL vial) strengths in single-dose vials. Both formulations are anticipated to launch in December. |
